Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASP546C in CLDN18.2-expressing advanced solid tumors
jRCT2031260058Phase 2Recruiting
- Sponsor
- Astellas Pharma
- Start
- Jun 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 2
01
Overview
Phase 2, open-label trial of ASP546C in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC) and 7 more (4 arms), sponsored by Astellas Pharma. Started Jun 2026; status: recruiting.
02
Drugs
ASP546C
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)pancreatic adenocarcinoma (PDAC)cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on jRCT2031260058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260058.